Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy

Clinical Neuropharmacology

Volumn 23, Issue 6, 2000, Pages 304-317

  Apelqvist, Gustav ^a   Wikell, Cecilia ^b   Carlsson, Björn ^b   Hjorth, Stephan ^c   Bergqvist, Peter B F ^a   Ahlner, Johan ^b   Bengtsson, Finn ^b,d  

^a LUND UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressant; Enantiomer; Monoamines; Open field behavior; Portacaval shunt

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; DRUG METABOLITE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; HEPATIC ENCEPHALOPATHY; MALE; NEUROTRANSMISSION; NONHUMAN; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CITALOPRAM; DOPAMINE; HEPATIC ENCEPHALOPATHY; HYDROXYINDOLEACETIC ACID; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NOREPINEPHRINE; POTASSIUM CHLORIDE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM;

EID: 0034526624     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200011000-00003     Document Type: Article

References (83)

1. Neurotransmission failure in hepatic encephalopathy involving the combined action of different brain tryptophan-related pathology. A speculative synthesis
2. Current theories on the pathogenesis of hepatic encephalopathy
3. Encephalopathy in patients with cirrhosis of the liver: A neuropsychological study
4. Subclinical hepatic encephalopathy impairs daily functioning
5. Chronic hepatic encephalopathy: A psychometrical study
6. Subclinical hepatic encephalopathy: Detection, prevalence and relationship to nitrogen metabolism
7. Neuropsychiatric sequelae of portal-systematic encephalopathy: A review
8. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals
9. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivate
10. Tolerability and safety of citalopram
11. Citalopram: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
12. Drug treatment of depression in the 1990s: An overview of achievements and future possibilities
13. Brain tryptophan perturbations in hepatic encephalopathy: Implications for effects by neuropsychiatric drugs in clinical practice
14. Central versus peripheral spontaneous behavioral abnormalities in experimental hepatic encephalopathy
15. Brain monoamine metabolism and behavior in portacaval-shunted rats
16. Portacaval shunt in the rats: Selective alterations in behavior brain serotonin
17. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology
18. Discordant motor activity levels of portacaval shunted rats in runway swim tests
19. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacaval-shunted rats
20. Effects of chronic experimental liver dysfunction and L-tryptophan on behavior in the rat
21. Experimental hepatic encephalopathy: Changes of the level of wakefulness in the rat with portacaval shunt
22. Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field
23. Loss of day-night rhythm in rats after portacaval shunt
24. Portal-systematic shunting and the disruption of circadian locomotor activity in the rat
25. Disruption of circadian locomotor activity in rats after portacaval anastomosis is not gender-dependent
26. Portacaval anastomosis disrupt circadian locomotor activity and pineal melatonin rhythms in rats
27. Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval shunted rat
28. Brain monoamines after portacaval anastomosis
29. Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy
30. Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: Serial analysis in plasma and cerebrosphinal fluid during treatment with an adapted amino acid solution
31. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
32. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systematic encephalopathy
33. p-chloroamphetamine- and d-fenfluramine induced brain serotonin release in experimental portal-systematic encephalopathy
34. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: Implications for thymoleptic drug safety in liver insufficiency
35. Portocaval shunt in the rat
36. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt
37. In vivo microdialysis evidence for central serotonin1 A and serotonin1 B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol
38. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine
39. 14C]2-deoxy D-glucose autoradiography
40. Basic characteristics of noradrenaline release in the hippocampus of intact and 6-hydroxydopamine-lesioned rats as studied by in vivo microdialysis
41. Solid-phase extraction with end-capped C2 columns for the routine measurements of racemic citalopram and metabolites in plasma by high-performance liquid chromatography
42. Determination of enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC
43. The portacaval and splenocaval shunt in the normal rat: A morphometric and functional reevaluation
44. Gender-dependent reduction of spontaneous motor activity and growth in rats subjected to portacaval shunt
45. Pharmacokinetics of paroxetine in patients with cirrhosis
46. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease
47. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses
48. Safety of fluvoxamine for patients with chronic liver disease: Biochemical variables, psychometric performance and EEG
49. The pharmacokinetics of paroxetine in patients with liver cirrhosis
50. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis
51. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function
52. Pharmacokinetics of newer antidepressants: Clinical relevance
53. New antidepressants: Use in high-risk patients
54. Brain tryptophan/serotonin perturbations in metabolic encephalopathy and the hazards involved when using psychoactive drugs
55. Failure of selective serotonin re-uptake inhibition to worsen the mental state of patient with subclinical hepatic encephalopathy
56. Cerebral flavin-containing monooxygenase-mediated metabolism of antidepressants in brain: Immunochemical properties and immunocytochemical localization
57. Xenobiotic metabolism in brain
58. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation
59. The pharmacokinetics of citalopram
60. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram
61. Brain 5-hydroxytryptamine metabolism after portacaval anastomosis: Relationship with ambulation
62. Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo
63. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo
64. Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inihibitors
65. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex
66. Effects of antidepressant agents on the synthesis of brain monoamines
67. Down regulation of striatal dopamine receptors in experimental hepatic encephalopathy
68. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis
69. Manganese toxicity dopaminergic dysfunction and hepatic encephalopathy
70. Dopamine and serotonin matabolism in hepatic encephalopathy
71. Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine
72. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram
73. The pharmacology of citalopram
74. 5-HT4 receptor involvement in the serotonin-enhanced dopamine efflux from the substantia nigra of freely moving rat: A microdialysis study
75. Alpha2-adrenergic receptor blocked markedly potentiate duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats
76. Serotonin-mediated increase in prefrontal cortex dopamine release: Pharmacological characterization
77. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy
78. Alterations in ingestive behavior following experimental portacaval anastomosis in rats
79. The effects of lesion in the mesencephalic raphe systems on male rat sexual behavior and locomotor activity
80. The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence
81. Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges
82. The revised monoamine theory of deppression: A modulatory role of monoamines, based on new findings from monoamine depletion experiments in humans